Tocilizumab
Products in Health Canada’s databases that list Tocilizumab as a medicinal or active ingredient, under this spelling. The same substance can be listed under another name (a salt, a common name), which has its own page.
- Drug products
- 15
- 15 authorized now
- Natural health products
- 0
- 0 active licences
- Notices of Compliance
- 37
- Products in all
- 15
Drug products
Authorized products first.
| Name | DIN | Status | Holder | Status since |
|---|---|---|---|---|
| ACTEMRA (80 MG) | 02350092 | Marketed | Hoffmann-La Roche Limited | |
| ACTEMRA (200 MG) | 02350106 | Marketed | Hoffmann-La Roche Limited | |
| ACTEMRA (400 MG) | 02350114 | Marketed | Hoffmann-La Roche Limited | |
| ACTEMRA (162 MG) | 02424770 | Marketed | Hoffmann-La Roche Limited | |
| ACTEMRA (162 MG) | 02483327 | Marketed | Hoffmann-La Roche Limited | |
| AVTOZMA (80 MG) | 02562022 | Marketed | Celltrion Inc. | |
| AVTOZMA (200 MG) | 02562030 | Marketed | Celltrion Inc. | |
| AVTOZMA (400 MG) | 02562049 | Marketed | Celltrion Inc. | |
| AVTOZMA (162 MG) | 02562057 | Marketed | Celltrion Inc. | |
| AVTOZMA (162 MG) | 02562065 | Marketed | Celltrion Inc. | |
| TYENNE (80 MG) | 02552450 | Marketed | Fresenius Kabi Canada Ltd | |
| TYENNE (200 MG) | 02552469 | Marketed | Fresenius Kabi Canada Ltd | |
| TYENNE (400 MG) | 02552477 | Marketed | Fresenius Kabi Canada Ltd | |
| TYENNE (162 MG) | 02552485 | Marketed | Fresenius Kabi Canada Ltd | |
| TYENNE (162 MG) | 02552493 | Marketed | Fresenius Kabi Canada Ltd |
Notices of Compliance
Approvals of drug submissions that list it, newest first.
- AVTOZMAAugust 4, 2026 · NOC 38033
- TYENNEAugust 4, 2026 · NOC 38043
- TYENNEMay 1, 2026 · NOC 37453
- ACTEMRAApril 22, 2026 · NOC 37372
- AVTOZMAOctober 16, 2025 · NOC 36201
- TYENNEOctober 11, 2024 · NOC 34185
- ACTEMRA SCDecember 6, 2023 · NOC 32312
- ACTEMRA SCOctober 27, 2022 · NOC 29323
- ACTEMRAOctober 13, 2022 · NOC 29188
- ACTEMRASeptember 26, 2022 · NOC 29087
- ACTEMRAMarch 10, 2022 · NOC 27746
- ACTEMRAApril 15, 2021 · NOC 25683
- ACTEMRA IV; ACTEMRA SCJanuary 4, 2021 · NOC 24925
- ACTEMRA SCOctober 9, 2020 · NOC 24433
- ACTEMRA IVOctober 9, 2020 · NOC 24434
- ACTEMRA; ACTEMRA SCJune 10, 2020 · NOC 23765
- ACTEMRAAugust 16, 2019 · NOC 22565
- ACTEMRA SCJuly 29, 2019 · NOC 22474
- ACTEMRAMarch 21, 2019 · NOC 21996
- ACTEMRANovember 28, 2018 · NOC 21571
- ACTEMRA; ACTEMRA SCSeptember 7, 2018 · NOC 21305
- ACTEMRAOctober 27, 2017 · NOC 19972
- ACTEMRAAugust 30, 2017 · NOC 19734
- ACTEMRAJuly 12, 2016 · NOC 18260
- ACTEMRAMarch 21, 2016 · NOC 17893
- ACTEMRAOctober 29, 2015 · NOC 17425
- ACTEMRADecember 23, 2014 · NOC 16468
- ACTEMRAOctober 7, 2014 · NOC 16155
- ACTEMRAMay 6, 2014 · NOC 15595
- ACTEMRADecember 5, 2013 · NOC 14989
- ACTEMRAOctober 17, 2013 · NOC 14823
- ACTEMRAMay 31, 2013 · NOC 14411
- ACTEMRAJanuary 19, 2012 · NOC 12935
- ACTEMRAOctober 20, 2011 · NOC 12724
- ACTEMRAAugust 31, 2011 · NOC 12585
- ACTEMRAJuly 21, 2011 · NOC 12503
- ACTEMRAApril 30, 2010 · NOC 11348